Neurology

Reader response: Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trial

It is very strange that Traboulsee et al.1 did not publish any MRI data; this does not allow a meta-analysis comparison with other trials. The Brave Dreams trial2 examined patients with relapsing-remitting MS (RRMS) undergoing percutaneous transluminal angioplasty (PTA) for chronic cerebrospinal venous insufficiency, and this Canadian study contains a mixed population of RRMS and secondary-progressive MS.1 Furthermore, a population with a mean age of 50 years and a disease duration of 17 years is not an acceptable study group for PTA

Source link




Related posts

De novo Mutation in CACNA1S Gene in a 20-Year-Old Man Diagnosed with Metabolic Myopathy.

Newsemia

Editors' note: Nutrients and bioactives in green leafy vegetables and cognitive decline: Prospective study

Newsemia

Reader response: Blood pressure from mid- to late life and risk of incident dementia

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy